Accessible Search Form

Skip left side navigation and go to content


Omnibus Grant Solicitations for Investigator-Initiated Applications

Please note that the Standard Due Dates changed in FY2016 to make funding recommendations and awards sooner.

Standard receipt dates are:
September 5, January 5, April 5 for all applications.

There is no separate receipt date for AIDS and AIDS-related applications.

The NHLBI accepts investigator-initiated grant applications relevant to the NHLBI mission through the Department of Health and Human Services Omnibus Grant Solicitations. While NHLBI has identified Topics of Special Interest (see below), the NHLBI also encourages mission-aligned applications for innovative technologies outside these targeted areas.

  • Phase I, Phase II, and Fast-Track applications are accepted through the Omnibus Grant Solicitations:

For important information about NHLBI's participation in the NIH SBIR/STTR program, please see p. 104 of Program Descriptions and Research Topicsimage of PDF icon (1 MB).

Total funding support (direct costs, indirect costs, fee) typically cannot exceed a hard cap of $225,000 for Phase I awards, or $1,500,000 for Phase II awards. NIH has received a waiver from the Small Business Administration (SBA) to provide awards that exceed the standard budget guidelines for specific topics. For the list of topics approved for awards over statutory budget limitations, see Appendix A (pp. 169 and 175) of the Program Descriptions and Research Topics document for more information and a list of topics. Projects that fit these topics are not guaranteed to be awarded the requested budget. For budgetary, administrative, or programmatic reasons, NHLBI may not fund an application or may decrease the length or budget of an award. Applicants considering requesting a budget greater than the statutory budget limits are strongly encouraged to contact us before submitting an application.

Small Business Topics of Special Interest for Fiscal Year 2017

Topics are listed here to inform potential applicants about areas of special interest to the NHLBI. Applications submitted in response to the Omnibus Grant Solicitations are NOT limited to the research and development areas described below.

Topic Code: HLS17-01, HLS17-02HLS17-03, HLS17-04, HLS17-05, HLS17-06, HLS17-07, HLS17-08, HLS17-09, HLS17-10, HLS17-11, HLS17-12, HLS17-13, HLS17-14, HLS17-15, HLS17-16, HLS17-17

Instructions for submitting applications in response to the following areas:

  • At the beginning of the title, please include the following four characters: HLS- (Important: according to the NIH's SF424 (R&R) Application Guideimage of PDF icon (2.6 MB). NIH limits title character length to 200 characters including the spaces between words and punctuation. Titles in excess of 200 characters will be truncated).
  • In the first sentence of the abstract, please include the code shown in the last column of the table below. This coding is for internal NHLBI tracking purposes only.
Topic Contact Code

Animal and Cellular Models:

  • for rare non-malignant and  pre-malignant (MDS & MPD) hematologic disorders
  • for complications associated with thrombosis
  • for transfusion of blood products or cell-based  therapies

Phyllis Mitchell,

Research tools: Imaging, reagents, assays including microassays, microfluidics, bioinformatics and nanotechnology for investigations of blood diseases, transfusion and cellular therapies 

Phyllis Mitchell,

Diagnostics: devices, biomarkers, imaging, and assays for non-malignant blood disorders  

Phyllis Mitchell,

Therapeutics: drugs, blood product and cellular therapies, and gene therapy for non-malignant blood disorders  

Phyllis Mitchell,

E-medicine Apps for patients and medical professionals to improve the management of and reduce the impact of non-malignant blood diseases 

Phyllis Mitchell,

Development of molecular imaging reagents/techniques and nanotechnology-based drug delivery systems that detect and allow for specific targeting of lung diseases, such as plexiform lesions in PAH (pulmonary arterial hypertension), microvascular loci susceptible to rarefaction/pruning in obstructive airway diseases like emphysema, or fibrotic triggers in IPF (idiopathic pulmonary fibrosis).

Sara Lin, HLS17-06

Development of reagents and methods to identify and isolate stem/progenitor cells, and direct differentiation to specific functional organ units. These reagents may include antibodies for stem/progenitor cell detection and sorting, biomaterials for optimizing the microniches of stem/progenitor cells, as well as methods for 3-D regeneration of tissue.

Sara Lin, HLS17-07

Development and validation of techniques(or algorithms) to study the microbiome in situ, including, but not limited to:

  • Sampling the microbiome of different lung or gut segments while minimizing contamination from other locations.
  • Development of an analytical system to study the metabolic products of the lung and gut microbiome from breath condensate.

Lis Caler, HLS17-08

Characterization and in vivo or in vitro applications of miRNA panels that target lung-resident mesenchymal or fibroblast cells and directly or indirectly promote lung repair or regeneration.

Sara Lin, HLS17-09

Development of high throughput methods to apply microfluidics technology in discovery of molecular profiles (DNAs, RNAs, proteins, or metabolites) in a large number of sputum or exhaled breath condensate samples collected from lung disease patients.  

Lisa Postow, HLS17-10

High-definition, conformal, biocompatible mesh technologies made from nanoscale materials are revolutionizing electronic-tissue interfaces. Applications that leverage this technology should expand or enhance the ability of present systems to monitor and treat cardiovascular and pulmonary disorders such as arrhythmias, sleep apnea, asthma, and COPD.

David Lathrop, HLS17-11

Develop new and improved methods to assess, monitor, or predict cardiovascular toxicity of therapeutic agents. Methods or assay platforms that utilize in vitro (e.g., re-programmed cells and engineered 3D-tissue constructs) and in silico approaches are encouraged.

Bishow Adhikari, HLS17-12

For citizens returning to an urban environment after release from prison or jail, develop and validate mobile app solutions they can use to improve their health outcomes related to cardiovascular diseases including but not limited to hypertension. For example, these solutions should use evidence-based guidelines for the management of cardiovascular disease such as care planning, medication management, assessment or monitoring of cardiovascular disease and decision support that includes multi-level (health systems, provider, and patient) facets. Solutions should also include user support documentation for all potential users of the technology, including but not limited to patients, family/caregivers, and providers.

Erin Iturriaga, HLS17-13

New animal models for the study of chronic venous insufficiency (CVI) and post-thrombotic syndrome, and innovative approaches for their prevention and treatment.

Cheryl McDonald, HLS176-14

Development of mechanical circulatory support devices for individuals with congenital heart disease and single ventricle physiology after Fontan surgical palliation.

Kristin Burns, HLS17-15

Novel non-invasive strategies that detect early subclinical changes in cardiac structure, function, and /or tissue are needed to improve detection and monitoring of chemotherapy-induced cardiac injury in order to improve cardioprotection and effectiveness of cancer therapeutics. Strategies that increase sensitivity and precision of existing or enhance imaging technologies with respect to normal and altered cardiac structure, function, energetics, and metabolism are sought. Pre-clinical or patient studies using molecular changes or biomarkers to enhance early detection of cardiac derangements are also responsive.

Patrice Desvigne-Nickens, HLS17-16

Develop innovative technology and/or service delivery models or designs to increase the adoption, uptake, and sustainability of evidence-based guideline recommendations for the management of heart, lung, blood, and sleep disorders. These should include multi-level (health systems, provider, and patient) facets and benefit ethnic/racial minority groups, rural populations, and low socioeconomic status groups.

Uche Sampson, HLS17-17

For questions, contact us.

Last Updated January 2017

Twitter iconTwitter external disclaimer Facebook iconFacebook external disclaimer YouTube iconYouTube external disclaimer Google+ iconGoogle+ external disclaimer